Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05407740Completed

"Association of Proteinuria and Progression of Kidney Dysfunction in Sickle Cell Disease"Disease

Role: lead

NCT05649280Completed

Safety Evaluation of DREPADOM - Home Care Services and Hospitalizations for Sickle Cell Disease Patients

Role: lead

NCT03032055Unknown

Validation of a Predictive Score of Acute Chest Syndrome

Role: lead

All 3 trials loaded